BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 12165893)

  • 1. The incidence of hearing impairment after successful treatment of neuroblastoma.
    Simon T; Hero B; Dupuis W; Selle B; Berthold F
    Klin Padiatr; 2002; 214(4):149-52. PubMed ID: 12165893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
    Bertolini P; Lassalle M; Mercier G; Raquin MA; Izzi G; Corradini N; Hartmann O
    J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
    Freilich RJ; Kraus DH; Budnick AS; Bayer LA; Finlay JL
    Med Pediatr Oncol; 1996 Feb; 26(2):95-100. PubMed ID: 8531860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
    Häberle B; Bode U; von Schweinitz D
    Klin Padiatr; 2003; 215(3):159-65. PubMed ID: 12778356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
    Lanvers-Kaminsky C; Krefeld B; Dinnesen AG; Deuster D; Seifert E; Würthwein G; Jaehde U; Pieck AC; Boos J
    Pediatr Blood Cancer; 2006 Aug; 47(2):183-93. PubMed ID: 16302218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hearing loss caused by high dose carboplatin therapy].
    Lautermann J; Adamczyk M; ten Cate WJ; Kloke O
    Laryngorhinootologie; 1998 Feb; 77(2):82-4. PubMed ID: 9555700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development.
    Knight KR; Kraemer DF; Neuwelt EA
    J Clin Oncol; 2005 Dec; 23(34):8588-96. PubMed ID: 16314621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience of the Izmir Pediatric Oncology Group on Neuroblastoma: IPOG-NBL-92 Protocol.
    Olgun N; Kansoy S; Aksoylar S; Cetingul N; Vergin C; Oniz H; Sarialioglu F; Kantar M; Uysal K; Tuncyurek M; Kargi A; Aktas S; Bayol U; Karaca I; Arikan A; Balik E; Aktug T; Elmas N; Kovanlikaya A; Kinay M; Anacak Y; Degirmenci B; Burak Z
    Pediatr Hematol Oncol; 2003; 20(3):211-8. PubMed ID: 12637217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of chemotherapy regimen using ifosphamide and carboplatin on recurrent or refractory neuroblastoma].
    Zhen ZJ; Sun XF; Xia Y; Wang ZH; Ling JY
    Ai Zheng; 2006 Dec; 25(12):1550-2. PubMed ID: 17166384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.
    Cheung NK; Kushner BH; LaQuaglia M; Kramer K; Gollamudi S; Heller G; Gerald W; Yeh S; Finn R; Larson SM; Wuest D; Byrnes M; Dantis E; Mora J; Cheung IY; Rosenfield N; Abramson S; O'Reilly RJ
    Med Pediatr Oncol; 2001 Jan; 36(1):227-30. PubMed ID: 11464891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel intensive induction therapy for high-risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hematopoietic support.
    Pradhan KR; Johnson CS; Vik TA; Sender LS; Kreissman SG
    Pediatr Blood Cancer; 2006 Jun; 46(7):793-802. PubMed ID: 16206215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma.
    De Bernardi B; Nicolas B; Boni L; Indolfi P; Carli M; Cordero Di Montezemolo L; Donfrancesco A; Pession A; Provenzi M; di Cataldo A; Rizzo A; Tonini GP; Dallorso S; Conte M; Gambini C; Garaventa A; Bonetti F; Zanazzo A; D'Angelo P; Bruzzi P;
    J Clin Oncol; 2003 Apr; 21(8):1592-601. PubMed ID: 12697885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma.
    Parsons SK; Neault MW; Lehmann LE; Brennan LL; Eickhoff CE; Kretschmar CS; Diller LR
    Bone Marrow Transplant; 1998 Oct; 22(7):669-74. PubMed ID: 9818694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.
    Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
    Eur J Cancer; 2009 Dec; 45(18):3213-9. PubMed ID: 19850470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma.
    Kushner BH; Budnick A; Kramer K; Modak S; Cheung NK
    Cancer; 2006 Jul; 107(2):417-22. PubMed ID: 16779793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cisplatin and carboplatin-induced ototoxicity in children: clinical aspects and perspectives for prevention].
    Montaguti M; Brandolini C; Ferri GG; Hatzopoulos S; Prete A; Pession A
    Acta Otorhinolaryngol Ital; 2002 Feb; 22(1):14-8. PubMed ID: 12236007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of efficacy of treatment for 30 children with neuroblastoma].
    Sun XF; Liu DG; Su YS; Lin TY; Chen XQ; He YJ
    Ai Zheng; 2003 Dec; 22(12):1343-5. PubMed ID: 14693065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma.
    Kushner BH; Kramer K; LaQuaglia MP; Modak S; Yataghene K; Cheung NK
    J Clin Oncol; 2004 Dec; 22(24):4888-92. PubMed ID: 15611504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ototoxicity of cisplatin in children with malignant diseases].
    Hadjilaskari P; Fengler R; Hartmann R; Henze G
    Klin Padiatr; 1989; 201(4):316-21. PubMed ID: 2779137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption.
    Neuwelt EA; Gilmer-Knight K; Lacy C; Nicholson HS; Kraemer DF; Doolittle ND; Hornig GW; Muldoon LL
    Pediatr Blood Cancer; 2006 Aug; 47(2):174-82. PubMed ID: 16086410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.